CatalystMarker
← board

XERS

distress 1/10 · well-funded / low risk
$8.19-2%today-17% from 52w high
xerispharma.com435 employeesFounded 2005Chicago, ILDrug Manufacturers - Specialty & Generic
Revenue
$83M
Liquidity
$112M
Runway
Shares 1y
+7%

Price & events

+7.6% over 6M
$5.29$7.11$8.94Jan 26Apr 26Jul 266.3Mfinancing: 8-K private_placement (2026-07-17)financing: 8-K private_placement (2026-06-11)rating: HC Wainwright & Co.: Buy (2026-03-02)
CatalystRating changeDilutionFinancingdashed = today
-2.3%
1D
-5.8%
1W
+13.7%
1M
+37.6%
3M
+10.0%
6M
+59.9%
1Y
+222.2%
2Y
+143.6%
5Y
+54.1%
All

Overview

Market Cap
$1.41B
Enterprise Value
$1.52B
Volume
150.19K
52 Week Range
$5.00 – $9.90
Total Shares
172.64M
Float Shares
166.58M
Short %
7.65%
% Held by Insiders
3.38%
% Held by Institutions
62.61%
RVOL
0.07x
Beta
0.85

Pipeline · 0 trials · 0 upcoming

ReadoutPhaseDrugIndicationEnrollStatus
No pipeline trials tracked.

Catalyst news & presentations · 1

Approved drugs (2)

  • GVOKE KITGLUCAGON2019 · Prescription
  • KEVEYISDICHLORPHENAMIDE1958 · Prescription

Capital structure — dilution & financing

Shares out: 172,642,055 · 0 offerings/1y · 2 PIPEs
  • 2026-07-178-Kprivate_placement
  • 2026-06-118-Kprivate_placement
  • 2025-05-13EFFECTshelf_effective
  • 2025-03-06S-3shelf_registration
🔒 Positioning — Pro
Short interest / days-to-cover, insider buys & sells.
Upgrade to Pro
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to Pro

Wall St ratings

strong buy · target $11 (+38% upside) · 7 analysts
  • 2026-03-02HC Wainwright & Co.Buy
  • 2026-01-09HC Wainwright & Co.Buy
  • 2025-12-09BarclaysOverweight
  • 2025-11-07OppenheimerOutperform
  • 2025-11-07HC Wainwright & Co.Buy
  • 2025-11-07Piper SandlerNeutral

Competitors

  • none identified

Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.